CardioPrecision Ltd has developed an innovative and multi-patented technology that allows clinicians to perform minimally invasive interventions through a very small access in the neck. Key benefits include much less pain and faster recovery than current approaches. Secondary benefits may include reduced blood loss, lower rates of transfusion/infection and much shorter hospital stay. The company’s CoreVista® devices have successfully been used in both Surgical Aortic Valve Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) procedures. Other cardiovascular applications (TMVR, TEVAR, EVAR, LVAD implantation etc. are envisaged with similar benefits for patients and healthcare providers.